Skip to main content


Fig. 2 | EJNMMI Research

Fig. 2

From: [68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?

Fig. 2

A 77-year-old patient with PCa, Gleason score 9, and PSA 13.5 ng/ml. a [68Ga]Ga-PSMA-11 PET/CT performed for staging showed extensive local disease as well as metastatic disease to pelvic lymph nodes and numerous skeletal metastases. b PSA levels declined by 25% to 10.8 ng/ml after 4.5 months of treatment with abiraterone (biochemical stable disease). Follow-up PET/CT showed stable disease in soft tissue, however, marked progression was noted in bone, with more extensive known lesions as well as new lesions. Imaging response was categorized as “progressive-disease.” The arrows in c and d indicate an example of a new PSMA-avid sclerotic bone lesion. This patient was continued on the same treatment and had marked progression on a recent follow-up PET as well as elevation of serum PSA to 36 ng/ml

Back to article page